Literature DB >> 35346729

The roles of N6-methyladenosine methylation in the regulation of bone development, bone remodeling and osteoporosis.

Yuan Li1, Li Meng2, Baobing Zhao3.   

Abstract

N6-methyladenosine (m6A), a novel epitranscriptomic RNA modification, plays crucial roles in a variety of biological processes and diseases. Recently, there are growing evidence supporting that m6A methylation is essential for bone development and homeostasis through the regulation of key genes by regulating RNA stability, localization, turnover and translation efficiency. In this review, we summarized our current understanding of the functional roles of m6A methylation and its related regulators in bone development and bone remodeling. These findings will offer new directions and insights on the further investigations of m6A methylation in bone biology. Moreover, we also discussed important advances of m6A methylation related regulators as potential therapeutic targets, which allows for novel therapeutic strategies on the medications of bone-related diseases including osteoporosis.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone development; Epigenetics; N(6)-methyladenosine methylation; Osteoporosis; RNA modification

Mesh:

Substances:

Year:  2022        PMID: 35346729     DOI: 10.1016/j.pharmthera.2022.108174

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   13.400


  2 in total

Review 1.  The roles of circRNA-miRNA-mRNA networks in the development and treatment of osteoporosis.

Authors:  Manqi Gao; Zhongkai Zhang; Jiabin Sun; Bo Li; Yuan Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-05       Impact factor: 6.055

2.  Relationship between indices of circulating blood cells and bone homeostasis in osteoporosis.

Authors:  Yuan Li; Weimin Hao; Jianming Guan; Bo Li; Li Meng; Shuangjiao Sun; Tianyuan Sheng; Shuangxi Dong; Qian Zhou; Mingjie Liu; Zhongkai Zhang; Tao Shen; Yuemao Shen; Baobing Zhao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-05       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.